Raymond James Financial Services Advisors Inc. Trims Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Raymond James Financial Services Advisors Inc. decreased its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPTGet Rating) by 8.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 11,631 shares of the biotechnology company’s stock after selling 1,012 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Sarepta Therapeutics were worth $1,286,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of SRPT. Wellington Management Group LLP boosted its position in shares of Sarepta Therapeutics by 33.6% in the first quarter. Wellington Management Group LLP now owns 2,680,478 shares of the biotechnology company’s stock worth $209,399,000 after acquiring an additional 673,725 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Sarepta Therapeutics by 2.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 1,163,847 shares of the biotechnology company’s stock worth $87,242,000 after purchasing an additional 27,042 shares during the period. Bellevue Group AG boosted its holdings in shares of Sarepta Therapeutics by 39.2% in the 1st quarter. Bellevue Group AG now owns 1,151,159 shares of the biotechnology company’s stock valued at $89,929,000 after purchasing an additional 324,418 shares during the last quarter. Federated Hermes Inc. increased its holdings in shares of Sarepta Therapeutics by 3.6% during the 1st quarter. Federated Hermes Inc. now owns 703,583 shares of the biotechnology company’s stock worth $54,964,000 after buying an additional 24,609 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Sarepta Therapeutics by 2.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 479,285 shares of the biotechnology company’s stock worth $37,442,000 after buying an additional 11,006 shares during the period. Institutional investors and hedge funds own 87.31% of the company’s stock.

Insiders Place Their Bets

In other news, Director Stephen Mayo sold 858 shares of the company’s stock in a transaction dated Thursday, November 17th. The shares were sold at an average price of $109.92, for a total value of $94,311.36. Following the sale, the director now owns 6,387 shares in the company, valued at approximately $702,059.04. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 6.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on SRPT shares. Needham & Company LLC upped their price target on Sarepta Therapeutics from $158.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, January 10th. The Goldman Sachs Group raised their price target on shares of Sarepta Therapeutics from $152.00 to $171.00 and gave the company a “buy” rating in a report on Thursday, November 3rd. Robert W. Baird increased their price objective on shares of Sarepta Therapeutics from $110.00 to $152.00 in a research report on Thursday, November 3rd. Cowen lifted their target price on shares of Sarepta Therapeutics from $114.00 to $125.00 in a report on Wednesday, January 11th. Finally, Cantor Fitzgerald increased their price target on Sarepta Therapeutics from $150.00 to $174.00 in a report on Tuesday, December 13th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $149.07.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $127.80 on Friday. The company has a quick ratio of 3.99, a current ratio of 4.36 and a debt-to-equity ratio of 3.58. Sarepta Therapeutics, Inc. has a fifty-two week low of $61.28 and a fifty-two week high of $134.08. The business has a 50 day moving average price of $121.49 and a two-hundred day moving average price of $110.05. The firm has a market cap of $11.22 billion, a PE ratio of -15.57 and a beta of 1.04.

Sarepta Therapeutics (NASDAQ:SRPTGet Rating) last released its earnings results on Wednesday, November 2nd. The biotechnology company reported ($2.94) EPS for the quarter, missing the consensus estimate of ($1.21) by ($1.73). The business had revenue of $230.30 million for the quarter, compared to analysts’ expectations of $234.55 million. Sarepta Therapeutics had a negative net margin of 81.76% and a negative return on equity of 97.37%. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.60) earnings per share. Sell-side analysts expect that Sarepta Therapeutics, Inc. will post -8.19 earnings per share for the current fiscal year.

Sarepta Therapeutics Profile

(Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

Featured Stories

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPTGet Rating).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.